simulect
novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunosuppressants - simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years).it is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
simulect 20mg powder and solvent for solution for injection vials
novartis pharmaceuticals uk ltd - basiliximab - powder and solvent for solution for injection - 20mg
simulect 10mg powder and solvent for solution for injection vials
novartis pharmaceuticals uk ltd - basiliximab - powder and solvent for solution for injection - 10mg
simulect powder lyophilized for solution for injection or infusion
novartis pharma stein ag - basiliximab - powder lyophilized for solution for injection or infusion - 20mg
simulect powder lyophilized for solution for injection or infusion
novartis pharma stein ag - basiliximab - powder lyophilized for solution for injection or infusion - 20mg glass vial and solvent in ampoule 5ml
simulect powder lyophilized for solution for injection or infusion
novartis pharma stein ag - basiliximab - powder lyophilized for solution for injection or infusion - 20mg
simulect powder for solution
novartis pharmaceuticals canada inc - basiliximab - powder for solution - 20mg - basiliximab 20mg - immunosuppressive agents
simulect 20 mg i.v vial powder and solvent for solution for injection
novartis pharma ag, switzerland - basiliximab - powder and solvent for solution for injection - 20 mg
simulect 20mg/vial powder & solvent for solution for injection or infusion 20 mg
شركة مستودع الأدوية الأردني - the jordan drugstore co - basiliximab 20 mg - 20 mg
simulect 20 mg
novartis israel ltd - basiliximab - powder and solvent for solution for injection/infusion - basiliximab 20 mg/vial - basiliximab - basiliximab - prophylaxis of acute organ rejection in de novo renal transplantation in combination with cyclosporin and corticosteroid based immunosuppression